If you are:
FDB Only When Necessary: RISK OF NEONATAL WITHDRAWAL SYNDROME WITH CHRONIC USE
Precaution: MONITOR FOR CHANGES IN RESPIRATION, GI EFFECTS, SEDATION, FEEDING PATTERN
No Known Risk: LOW LEVELS EXCRETED WITH LOW RISK FOR ADVERSE EFFECTS IN INFANT
An adult over 60:
management or monitoring precaution: Pulmonary-Life threatening respiratory depression is more likely to occur with high doses, SR products, cachexia, or debilitation due to altered pharmacokinetics with poor fat stores, muscle wasting, or altered clearance. Monitor closely at initiation and with dose titration. Neuro/Psych-Risk for increased confusion and delirium. May increase fall risk. Avoid treatment with 3 or more CNS active drugs. Gastrointestinal-Constipation risk. Urogenital-Urinary retention risk.
management or monitoring precaution: Hepatic-Elderly are more susceptible to hepatotoxicity. Strict adherence to a maximum daily dose of 3000mg is advised.
Giving oxycodone-acetaminophen-tablet-immediate-release-and-delayed-release-biphasic-tablet-ir-release-biphasic to a child under 12:
management or monitoring precaution: Use weight based dosing in children less than 12 years.
Contraindication: Risk for fatal respiratory depression. Increased sensitivity to effects and adverse effects. Controlled release form only in opioid tolerant patient age 11 years and older.
Severe Precaution: Consider risk for fatal respiratory depression in opioid naive patients. Restricted use for opioid tolerant patient. Increased sensitivity to effects and adverse effects.
Severe Precaution: Potential increased sensitivity to effects, adverse CNS effects and respiratory depression.